RE: Rns Out!!24 May 2021 08:10
“In vitro experiments were conducted at Viroclinics-DDL in the Netherlands to confirm that SNG001 had activity against the B.1.1.7 ("UK or "Kent") and B.1.351 ("South African") variants. In these experiments, Vero E6 cells were treated with SNG001 prior to and after infection with SARS-CoV-2. 16-24 hours after infection, the presence of SARS-CoV-2 viral proteins was determined using an immunostaining method. SNG001 potently reduced virus to undetectable levels in cells infected with "Wuhan-like" (virus strain: Germany/BavPat1/2020), the UK/Kent variant and the South African variant. Concentrations, readily achievable following inhaled delivery of interferon beta, that gave 90% inhibition (IC--90) were 3.2, 4.0 and 3.4 IU/mL respectively.”